Published in Women's Health Weekly, March 15th, 1999
The IND for ERA-923 is the second IND submitted for a compound emanating from the Ligand/Wyeth-Ayerst collaboration. On March 26, 1998, Wyeth-Ayerst submitted an IND for the tissue selective estrogen (TSE), TSE-424, for the treatment of post-menopausal osteoporosis.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly